Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

This study has been completed.
Genentech, Inc.
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center Identifier:
First received: December 22, 2007
Last updated: December 15, 2015
Last verified: December 2015
Results First Received: December 15, 2015  
Study Type: Interventional
Study Design: Endpoint Classification: Safety Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Ovarian Cancer
Fallopian Tube Cancer
Intervention: Drug: Paclitaxel,Cisplatin, Bevacizumab

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
All Patients Paclitaxel, Cisplatin, Bevacizumab

Participant Flow:   Overall Study
    All Patients  
STARTED     42  
COMPLETED     38  
Evaluable for toxicity only                 3  
Patien not treated                 1  

  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
All Patients Paclitaxel, Cisplatin, Bevacizumab

Baseline Measures
    All Patients  
Number of Participants  
[units: participants]
[units: participants]
<=18 years     0  
Between 18 and 65 years     40  
>=65 years     2  
[units: participants]
Female     42  
Male     0  

  Outcome Measures

1.  Primary:   Overall Objective Response   [ Time Frame: 2 years ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: Dr. Jason Konner
Organization: Memorial Sloan Kettering Cancer Center
phone: 646-888-4219

Responsible Party: Memorial Sloan Kettering Cancer Center Identifier: NCT00588237     History of Changes
Other Study ID Numbers: 06-064
Study First Received: December 22, 2007
Results First Received: December 15, 2015
Last Updated: December 15, 2015
Health Authority: United States: Institutional Review Board